Literature DB >> 12493538

Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation.

Dale O Kiesewetter1, Elaine M Jagoda, Chih-Hao K Kao, Ying Ma, Laura Ravasi, Kazuaki Shimoji, Lawrence P Szajek, William C Eckelman.   

Abstract

Paclitaxel (Taxol) is a clinically important chemotherapeutic agent. We describe the synthesis of fluoro-, bromo-, and iodopaclitaxel and their [(18)F]fluoro-, [(76)Br]bromo-, and [(124)I]iodo- analogues. [(18)F]Fluoropaclitaxel shows high uptake and rapid clearance from tissues in rats. Preadministration of paclitaxel in normal rats significantly increases (p < 0.005) retention of [(18)F]fluoropaclitaxel and [(76)Br]bromopaclitaxel in blood (33.0%), heart (32.0%), lung (37.6%) kidney (142.4%); and blood (33.4%), lung (42.3%), kidney (62.4%), respectively. [(18)F]Fluoropaclitaxel uptake in the brain of mdr1a/1b(-/-) mice is increased 1400% (p < 1.3e-07) relative to wild-type controls. Preadministration of paclitaxel or XR9576, a modulator, had little effect on the biodistribution in these mdr1a/1b(-/-) mice. As a result, [(18)F]fluoropaclitaxel will be a useful radiopharmaceutical for the study of multidrug resistant tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12493538     DOI: 10.1016/s0969-8051(02)00351-7

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  14 in total

1.  Automated radiochemical synthesis of [18F]FBEM: a thiol reactive synthon for radiofluorination of peptides and proteins.

Authors:  Dale O Kiesewetter; Orit Jacobson; Lixin Lang; Xiaoyuan Chen
Journal:  Appl Radiat Isot       Date:  2010-10-08       Impact factor: 1.513

2.  Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT.

Authors:  Karen A Kurdziel; Joseph D Kalen; Jerry I Hirsch; John D Wilson; Harry D Bear; Jean Logan; James McCumisky; Kathy Moorman-Sykes; Stephen Adler; Peter L Choyke
Journal:  J Nucl Med       Date:  2011-08-17       Impact factor: 10.057

3.  Rapid and simple one-step F-18 labeling of peptides.

Authors:  Orit Jacobson; Lei Zhu; Ying Ma; Ido D Weiss; Xilin Sun; Gang Niu; Dale O Kiesewetter; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2011-02-21       Impact factor: 4.774

Review 4.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Authors:  Severin Mairinger; Thomas Erker; Markus Muller; Oliver Langer
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

5.  [(76) Br]BMK-152, a nonpeptide analogue, with high affinity and low nonspecific binding for the corticotropin-releasing factor type 1 receptor.

Authors:  Elaine M Jagoda; Lixin Lang; Karen McCullough; Carlo Contoreggi; B Moon Kim; Ying Ma; Kenner C Rice; Lawrence P Szajek; William C Eckelman; Dale O Kiesewetter
Journal:  Synapse       Date:  2011-04-11       Impact factor: 2.562

6.  Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]Paclitaxel (FPAC).

Authors:  Joseph D Kalen; Jerry I Hirsch; Karen A Kurdziel; William C Eckelman; Dale O Kiesewetter
Journal:  Appl Radiat Isot       Date:  2006-12-11       Impact factor: 1.513

7.  Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients.

Authors:  Astrid A M van der Veldt; N Harry Hendrikse; Egbert F Smit; Martien P J Mooijer; Anneloes Y Rijnders; Winald R Gerritsen; Jacobus J M van der Hoeven; Albert D Windhorst; Adriaan A Lammertsma; Mark Lubberink
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

8.  The evolving role of nuclear molecular imaging in cancer.

Authors:  Ka Kurdziel; G Ravizzini; By Croft; Jl Tatum; Pl Choyke; H Kobayashi
Journal:  Expert Opin Med Diagn       Date:  2008-07

9.  Radiolabeling of HER2 specific Affibody(R) molecule with F-18.

Authors:  Dale O Kiesewetter; Gabriela Krämer-Marek; Ying Ma; Jacek Capala
Journal:  J Fluor Chem       Date:  2008-09       Impact factor: 2.050

Review 10.  Applications of LC-MS in PET radioligand development and metabolic elucidation.

Authors:  Ying Ma; Dale O Kiesewetter; Lixin Lang; Dongyu Gu; Xiaoyuan Chen
Journal:  Curr Drug Metab       Date:  2010-07       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.